鐢熺墿鍖栧/鐢熺悊瀛︿綔鐢ㄣ€怋iochem/physiol Actions銆 : Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.
鍚噺銆恆ssay銆 : 鈮?8% (HPLC)
褰㈡€併€恌orm銆 : powder
棰滆壊銆恈olor銆 : white to off-white
瑁呰繍銆恠hipped in銆 : wet ice
瀛樺偍娓╁害銆恠torage temp.銆 : -20鈩傸br/>瀹夊叏淇℃伅锛欬br/>绗﹀彿銆怱ymbol銆 : GHS08
淇″彿璇嶃€怱ignal word銆 : Warning
鍗卞澹版槑銆怘azard statements銆 : H361
璀︾ず鎬у０鏄庛€怭recautionary statements銆 : P281
鍗卞鐮?娆ф床)銆怘azard Codes (Europe)銆 : Xn
椋庨櫓澹版槑(娆ф床)銆怰isk Statements (Europe)銆 : 63
瀹夊叏澹版槑(娆ф床)銆怱afety Statements (Europe)銆 : 36/37
寰峰浗姘磋川鍗遍櫓鎬у垎绫汇€怶GK Germany銆 : 3